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Abstract. This case report describes a complex radical 3D-Conformal Radiotherapy treatment 
planning, dosimetric issues and outcome of definitive treatment of un-resectable carcinoma of 
the vulvar in a 42-year old lady. The patient presented with large fungating mass of the vulva 
which was biopsy confirmed as Keratinizing Squamous Cell Carcinoma. Further staging 
investigation revealed locally advanced disease (T4), with bilateral inguinal lymph nodes 
involvement. There is no systemic metastasis or intra-pelvic nodes. The patient was seen by 
Gynae-Oncology team and the disease was deemed un-resectable without significant morbidity. 
She was treated to a total dose of 64.8Gy in 36 fractions over 7 weeks with concurrent weekly 
Cisplatinum in 2 phases. 3D-Conformal radiotherapy technique using the modified segmental 
boost technique (MSBT, large PA and small AP photon fields with inguinal electron matching) 
was used. TLD chips were used for in-vivo dose verification in phase 1 and 2 of the treatment. 
At completion of planned radiotherapy, patient had a complete clinical response, grade 2-3 skin 
toxicity, grade 2 rectal toxicity, and grade 2 dysuria Vulval Squamous Cell Carcinomas are very 
radiosensitive tumours and the skills of the treating Radiation Oncologist, Dosimetrists, 
Physicist, Radiation Therapist and also nurses is of foremost importance is ensuring good clinical 
outcomes. 
1.  Introduction 
Squamous Cell Carcinoma (SCC) of the vulva is an uncommon cancer mostly associated with HPV 
viral infection. Two common histologies are described – the HPV 16, 18 and 33 associated basaloid or 
condylomatous SCC and non-HPV associated keratinizing SCC’s. In nearly 60% of vulval cancers, HPV 
infection is likely the causative factor. 
This case report will discuss the successful treatment of a Moderately Differentiated Keratinizing 
SCC of the vulva with definitive chemo-radiotherapy using the modified segmental boost technique 
(MSBT), large PA and small AP photon fields with inguinal electron matching. This technique is 
published in the literature for lower pelvic malignancies and Moran M et al in his paper described the 
use of single prescription point in MSBT. In Advanced Medical & Dental Institute (AMDI), we further 
modified this technique using dual prescription points in the phase I followed by further tumour and 
inguinal boost in phase II.  
A 42-year old lady with locally advanced SCC of the vulva was referred to AMDI Oncology Centre 
for radiotherapy opinion. She was earlier seen by Gynae-Oncological surgeon and her tumour was 
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deemed not resectable without significant morbidity. The patient written consent was obtained for 
publication of her case in this paper. 
A month earlier patient presented with 2 weeks’ history of labial swelling and a punch biopsy of the 
lesion revealed Moderately Differentiated SCC (see Figure 1). CT of the thorax/abdomen/pelvis then 
showed a heterogeneously enhancing lesion measuring 6.4 cm × 3.4 cm × 4.9 cm arising from left labia 
with suspicion of bladder, rectum and vaginal invasion. There were multiple inguinal nodes, largest 
measuring 2.7 cm. Otherwise no distant metastasis elsewhere (see Figure 2). 
 
 
 
Figure 1. Tumour at presentation 
 
 
 
 
 
 
 
Figure 2. Primary marked red and lymph nodes purple in the CT images, (a) CT slice showing the 
primary tumour, (b) CT slice showing the lymph nodes and (c) CT slice showing the primary tumour on 
another slice 
(a) 
(b) 
(c) 
31234567890
ISMP2016  IOP Publishing
IOP Conf. Series: Journal of Physics: Conf. Series 851 (2017) 012041  doi :10.1088/1742-6596/851/1/012041
 
 
 
 
 
 
The disease extend and treatment expectation was discussed in length with the patient. Mutual 
decision to treat her condition with concurrent chemo-radiotherapy with definitive intent was made. The 
plan at that time was to treat in 3 phases: phase I (36 Gy in 20 fraction) treating the whole pelvis, phase 
II (9 Gy in 5 fraction) to the true pelvis and phase III (18 Gy in 10 fraction) boost to the GTV concurrent 
with IV Cisplatinum 40mg/m2 weekly (See Figure 3). Patient is to be re-assessed after the phase I for 
consideration of bilateral inguinal lymph node dissection. 
 
 
Figure 3. Clinical photograph after the planned phase I of 36 Gy in 20 fraction (a) before treatment, 
(b) 1 week and (c) 2 weeks after the full course of treatment. 
 
CT simulation of the patient was repeated after the 18th fraction for the phase II planning since the 
tumour has shrunk significantly. The option of bilateral inguinal dissection was also discussed with the 
patient at that point. However, given the fact that inguinal nodes’ PTV/CTV was extending into the 
phase II pelvic field and also the delays in the phase II of definitive radiotherapy that maybe caused by 
subjecting patient to inguinal dissection, it was decided to proceed with definitive chemo-radiotherapy 
albeit accepting the significantly higher risk of bilateral lympoedema in future. As mentioned earlier, 
since the inguinal nodes’ PTV/CTV was extending into the true pelvic photon fields coupled with the 
fact that good bilateral femoral sparring was achieved with the MSBT technique it was decided to 
continue with the same phase I field arrangements to 46.8 Gy in 26 fractions. After completing phase I 
concurrent chemo-radiotherapy of 46.8 Gy the PTV-GTV is further boosted to 64.8Gy in 36 fractions. 
2.  Radiotherapy technique 
2.1 CT-Simulation 
Patient was CT-simulated with full bladder, in supine position, both legs flexed and abducted (frog-leg 
position) to open up the inguinal folds and immobilised with vac bag. Primary tumour was exhautivey 
bolused with extra care to ensure there is no air gap especially the posterior part of the tumour abutting 
the anus. Thickness of the bolus is approximated to around 1 cm. 3 mm CT-images obtained with IV 
contrast from umbilicus to mid-thigh. The same process was repeated for the phase II planning (PTV-
GTV boost) 
2.2 Planning 
In phase I, patient was treated with large AP field covering the bilateral inguinal region anterior superior 
iliac spine (ASIS laterally), L5/S1 superiorly and 2 cm below the tumour inferiorly while shielding the 
lateral part of bilateral thighs (see Figure 4a). Posteriorly (PA), a smaller true pelvic field was used with 
both superior and inferior borders corresponding to the AP field however lateral borders were kept at 
1.5 cm outside the pelvic brim (see figure 4b). 
For the AP field, the ICRU prescription point was placed at the left inguinal region at 3 cm depth 
and 46.8 Gy was prescribed to that point. Dose was topped from the PA field to ensure uniform pelvic 
phase I dose coverage. This is achieved by iteratively changing the PA beam prescription point and 
also prescribing a dose that compensates the AP beam. The PA beam was also attenuated superiorly 
(treating full field before partially shielding the superior portion as to attenuate the dose from the 
(a) (b) (c) 
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superior portion of the PA beam). This optimisation process uses iterative trial of different beam 
energy, prescription points, shielding and etc. Finally, an optimal T-shaped plan was achieved, 
sparring the femoral heads as shown in Figure 5 and Figure 6. 
The final plan was reviewed and we tried to conform to the ICRU 50 recommendations. The 
minimum PTV coverage of 95% for the volume of interest was aimed and at points where this is not 
achievable, the CTV coverage is ensured at least at 95% of prescribed dose. Though at a couple of points 
the maximum dose crossed the 107%, these spots were either in the bolus or inside the tumour itself. 
 
 
Figure 4. (a) large AP field with prescription point, (b) smaller PA field with prescription point 
 
 
Figure 5. Phase I coverage – pelvic and inguinal coverage with sparring of the bilateral femorals 
(isodose lines: 95% in red, 90% in orange). 
 
 
Figure 6. Electron-photon beam matching in phase II (isodose lines: 95% in red, 90% in orange). 
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In phase II, the primary tumour and the bilateral inguinal nodes were further boosted to 64.8 Gy in 
38 fractions (a further 18 Gy in 10 fractions). The primary tumour was boosted with single direct anterior 
10 MV photon beam matched bilaterally with electrons for the inguinal lymph nodes. The electron-
photon beam was matched at the skin where the was overlap. 
3.  Treatment and verification 
On the first day of the phase I treatment, extreme care was taken on bolusing the primary tumour to 
ensure there is no air gap and also correct bolus thickness. Cone beam CT was used to verify the 
positioning and also presence of any air gap.  
Four TLDs were places at different corners of the primary tumour as to verify the tumour dose 
coverage. In phase II, TLDs were also placed on the skin surface where the electron beams covers the 
inguinal region. The TLD readings was compared to MONACO 5 planning system dose distribution as 
in Figure 7. Mostly there is an overdose rather than underdose to the tumour as recorded by the TLD 
readings. Cone beam CT was performed once a week to ensure patient positioning is the same as per 
simulation. 
 
 
 
 
Figure 7. TLD readings at the start of phase I (a) and phase II (b) 
4.  Conclusions 
Though HPV associated basaloid or condylomatous SCC is considered the more radiosensitive, 
keratinizing SCC of vulva also do respond well to radiotherapy as seen in this patient (complete clinical 
response, CR). The skills and training of the treating radiation oncologist, dosimetrists, physicist, 
TLD location on tumour 
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radiation therapist and also nurses is of foremost importance is ensuring good clinical outcomes. This 
whole process had been very exhaustive, time consuming and resource intensive. 
Though there were discrepancies in the actual TLD reading compared to MONACO planning system, 
our team had been happy that it is more of overdosing the tumour rather than underdose. This 
discrepancy can also be attributed to the fact that the precise point of posterior and lateral TLD placement 
could not be ascertained with high accuracy unlike the anterior TLD placement point which was easily 
visible and identifiable. 
Though it is tempting to use IMRT in these type of difficult cases, there are many issues with IMRT 
such as confidence with not bolusing the tumour, or if bolused then ensuring the daily uniform thickness 
of the bolus, daily bladder variation, significant changes in the tumour dimensions during treatment and 
etc. As such, the use of 3D-CRT is the safest method in definitive radiotherapy of vulval carcinoma until 
a validated standard protocol on the use IMRT in vulval carcinomas is available. 
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